Skip to content Skip to menu

Government urged to move quickly on PC report

Tuesday, 16 September 2008

Media Release

Medicines Australia chief executive Ian Chalmers has urged the Government to implement the recommendations of the Productivity Commission’s new Annual Review of Regulatory Burdens on Business.

The review, released today, recommends a number of important measures which would significantly improve access to innovative new medicines for Australian patients.

Notably, the review recommends: The Pharmaceutical Benefits Advisory Committee should be allowed, when requested by applicants, to conduct its assessment of a medicine for PBS listing in parallel with the TGA’s assessment of the application to register the medicine.

“This one measure could reduce by a full year the time taken to list a new medicine on the PBS,” Mr Chalmers said.

Other key Productivity Commission recommendations include:

  • Increasing the cost threshold at which PBS listings require Cabinet approval
  • Reducing the time and cost of TGA approval processes
  • Introducing a harmonised national system for approving multi-centre clinical trials, to be implemented by the end of 2009.

Mr Chalmers said the Productivity Commission’s recommendations, if adopted, would mean that Australian patients would enjoy much faster access to important therapies.

“I call on the Government to implement these recommendations from the Productivity Commission as soon as possible,” Mr Chalmers said.

“Procedural rigour in the evaluation of medicines is important and must be maintained.

In this context, initiatives that bring innovative, safe and effective new medicines onto the PBS more quickly are great news for patients.”

Medicines Australia has been working closely with the Government to find ways of improving access to innovative new medicines for Australian patients.

Mr Chalmers acknowledged the importance of the Productivity Commission report, which made a raft of recommendations to reduce the burden of government regulation on business.

“I commend the Productivity Commission on a thorough and very constructive report,”

Mr Chalmers said. “I also look forward to a quick and positive response from the Government.”

–ENDS–

Contact Person:

Jamie Nicholson
Media Communications Manager
Phone: 0419 220 293
Email:
Jamie.Nicholson@medicinesaustralia.com.au

Information

As COVID19 continues to spread, our thoughts go out to anyone who has been infected or impacted. We hope that you are taking the necessary precautions to keep safe and well, both at work and at home.

Medicines Australia continues to monitor the situation and take advice from the Department of Health and the World Health Organisation. We are focused on responding to the important short-term issues but are also ensuring we stay balanced and maintain a focus on the medium and long-term business for our industry along with the well-being of our people.

At Medicines Australia we have initiated the following to ensure we support containment measures to provide business continuity and the well-being of our staff.

  • All non-essential travel has been restricted or cancelled
  • All face-to-face meetings (with external stakeholders and members) have been changed to virtual meetings (where appropriate)
  • Staff have been provided with the latest official information on COVID-19 through a hot-link on the office intranet; this information is regularly monitored and updated
  • Flexible working arrangements are covered in our HR policy which will allow staff to work remotely, if or when required
  • Current IT infrastructure enables staff to work remotely and will be in use if any person needs to self-isolate
  • Visual reminders have been displayed around the office, providing information about best hygiene practices
  • Extra hand-sanitiser, tissues and cleaning products have been supplied to staff for their work spaces

Our latest information is located at medicinesaustralia.com.au/covid-19/

Top